Please ensure Javascript is enabled for purposes of website accessibility

5 of Last Week's Biggest Winners

By Rick Munarriz – Mar 10, 2013 at 8:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These five companies soared this past week.

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.


March 8

Weekly Gain

Vical (VICL)



MGIC Investment (MTG 0.78%)



MBIA (MBI 0.23%)



James River Coal (NASDAQ: JRCC)



Amarin (AMRN)



Source: Barron's.

Vical -- a biotech working on a metastatic melanoma treatment that's in the late stages of clinical studies -- popped nicely higher after impressing investors at the Cowen and Company 33rd Annual Health Care Conference in Boston on Wednesday.

MGIC wowed investors with a 39% surge a week earlier, and it kept the party going with a 30% climb this time around. Mortgage insurance companies have been soaring as the housing market firms up, since that means less risk for the values of the homes that they're insuring. Rival MBIA also went along for the ride, moving 21% higher this past week on the same wave of improving fundamentals.

James River Coal initially tanked after posting a wider-than-expected quarterly deficit, but its plans to idle a few mines should save money at a time when the coal producer can certainly use it. After slumping through the first four days of the week, James River burst into positive territory with a 17% pop on Friday.

Amarin posted a much smaller deficit than Wall Street was expecting two weeks ago, but momentum is building for this quarter's launch of its flagship Vascepa drug. The first approved medication for the treatment of high triglyceride levels should mean big things for Amarin, and having nearly 25 million shares sold short should add fuel to any rally.

Longtime Fool contributor Rick Munarriz and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.